Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-adjustment of enoxaparin by a Bayesian pharmacological approach in pediatric renal transplant recipients
2021-000099-12Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of enoxaparin in Renal allograft thrombosis and renal vein thrombosis (RVT), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary: Anti-Xa activity within target range at 28-30 hours. Started Jul 2021; status: active.
02
Drugs
enoxaparin
03
Conditions
Renal allograft thrombosisrenal vein thrombosis (RVT)
Beyond the preview
Go deeper on 2021-000099-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000099-12.